Nothing is certain. However if results are similar or better than the previous study, it will be approved by the FDA. Given the p values, I'd say chances are very good. It will be worth several USD billion at that point. Investors have realised they're running out of time.
- Forums
- ASX - By Stock
- biosimilar aflibercept possibly imminent, Opthea more valuable to Regeneron?
Nothing is certain. However if results are similar or better...
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
77.3¢ |
Change
-0.018(2.22%) |
Mkt cap ! $929.4M |
Open | High | Low | Value | Volume |
79.0¢ | 79.0¢ | 74.5¢ | $705.0K | 920.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 207363 | 77.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
77.5¢ | 64990 | 19 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 208363 | 0.770 |
8 | 18655 | 0.765 |
17 | 170451 | 0.760 |
8 | 30167 | 0.755 |
8 | 522296 | 0.750 |
Price($) | Vol. | No. |
---|---|---|
0.775 | 64990 | 19 |
0.780 | 20602 | 9 |
0.785 | 50031 | 7 |
0.790 | 134583 | 3 |
0.795 | 412407 | 4 |
Last trade - 12.46pm 27/09/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |